10-Q · May 15, 2026
Outlook Therapeutics reported a significant net revenue of $127,439 for Q2 2026, marking a notable increase from zero in Q2 2025. Despite this, the company continued to incur substantial losses, amounting to $4,453,081…
Earnings analysis · 10-Q
OTLK earnings analysis
Filed August 18, 2026 · Our reading of the company's report
The latest report
The quarter showed sharply deteriorating commercial performance: revenue was only $9,000, down 92.9% sequentially and 99.6% year over year, while diluted EPS worsened to a $0.09 loss from a $0.05 loss. Although the…
Read full summary
The quarter showed sharply deteriorating commercial performance: revenue was only $9,000, down 92.9% sequentially and 99.6% year over year, while diluted EPS worsened to a $0.09 loss from a $0.05 loss. Although the August Offering provided $51.1 million of net proceeds, management says the resulting $62.3 million of cash and proceeds funds operations only into Q2 2027 and is insufficient for at least 12 months, creating substantial going-concern uncertainty. The company also faces $20.3 million of March 2026 Note obligations and ongoing litigation.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.09
What stood out
-
Revenue collapsed sequentially and year over year
Reported revenue of $9,000, down 92.9% from $127,439 in the prior quarter and 99.6% from $2.0 million in the year-ago quarter. Revenue was also 99.1% below the $1,013,336 consensus estimate.
-
Sequential EPS loss widened
Diluted EPS was a loss of $0.09 versus a loss of $0.05 in the prior quarter, a $0.04 sequential deterioration, but improved from a loss of $0.55 in the year-ago quarter.
-
August offering added $51.1M of net proceeds
The company reported $11.2 million of cash and cash equivalents at June 30, 2026, and disclosed $51.1 million of net proceeds from its August 2026 Offering.
-
Cash runway extends only into Q2 2027
Management stated that the combined $62.3 million of cash and offering proceeds is expected to fund operations only into the second quarter of calendar year 2027.
-
Disclosure controls assessed as effective
Management reported that disclosure controls were effective at the reasonable assurance level as of the end of the reporting period and that there were no material changes in internal control over financial reporting during the quarter ended June 30, 2026.
What to watch
-
Going-concern uncertainty and funding need
The filing states there is substantial doubt about the company’s ability to continue as a going concern because $11.2 million of June 30, 2026 cash plus $51.1 million of August offering proceeds will not fund operations through at least 12 months from the report date. Management expects to require substantial additional capital and says failure to obtain it could force a significant curtailment or cessation of operations.
-
Debt carries costly repayment terms
The company had $20.3 million of principal, accrued interest and exit fees outstanding under the March 2026 Note as of June 30, 2026. The note bears interest at prime plus 3%, subject to a 9.5% minimum, matures June 16, 2027, and Atlas may redeem up to $3.0 million per calendar quarter beginning September 16, 2026; cash payments are also subject to a 7.5% exit fee.
-
Pending securities and derivative litigation
A securities class action filed November 3, 2023 remains pending after the court dismissed the second amended complaint in part on December 23, 2025; plaintiffs filed a revised third amended complaint in April 2026. A related derivative action filed October 10, 2024 is stayed, and the company has established no reserve for potential liabilities.
-
Commercialization has not produced material revenue
LYTENAVA has been approved for marketing for wet AMD in the US, EU and UK, but the filing states the company has not generated material revenue from sales. The company expects increased expenses while it commercializes the product and continues to incur significant losses and negative operating cash flows.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that $11.2 million of cash and cash equivalents as of June 30, 2026, together with $51.1 million of net proceeds from the August 2026 Offering, is expected to fund operations only into the second quarter of calendar year 2027; the filing states these resources are insufficient for at least 12 months from the report date.
Earlier filings 4
10-Q · February 17, 2026
Outlook Therapeutics reported net revenue of $(1,207,833) and GAAP diluted loss per share of $(0.38) for the quarter ended December 31, 2025, missing the consensus EPS and producing negative net revenue driven by…
10-Q · August 14, 2025
Outlook Therapeutics reported first commercial revenue following its June 2025 launch of LYTENAVA, recording revenues of $1,505,322 and gross profit of $1,065,507 for the three months ended June 30, 2025. Despite the…
10-Q · May 15, 2024
Outlook Therapeutics reported a large quarterly net loss of $114,288,943 (net loss per share $8.01) driven primarily by non‑cash warrant and promissory note fair‑value adjustments; R&D spend ramped to $13,508,934 as the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.